PrimeGen US, a biotechnology company developing innovative stem cell and exosomes-based therapies, has entered into a definitive merger agreement with DT Cloud Star Acquisition Corporation (Nasdaq: DTSQ).[1][2] The agreement was dated February 2, 2026, and he announces it on February 4, 2026.[1] The transaction implies an equity value of PrimeGen US of approximately $1.5 billion.[1][2] PrimeGen is targeting a pre-clinical (Pre-IND) Triple Activated MSC stem cell platform for acute liver injury.[1] After the merger closes, expected in the second half of 2026, the combined company will operate as PrimeGen US and plans to list on the Nasdaq under the new ticker.[1][2] The closing is subject to shareholder approval of both companies, regulatory approvals, minimum cash terms and standard closing conditions.[1]